Ammar Ismail

Ammar Ismail

Auto-generated profile, based on publicly available information

Ammar Ismail

Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
AIAmmar Ismail
Ammar Ismail
ASAmr Muhammad Abdo Salem
Amr Muhammad Abdo Salem
AAAhmed M Afifi
Ahmed M Afifi
Mohamed Abdel-DaimMohamed Abdel-Daim
Mohamed Abdel-Daim

1 December 2017 in Journal of Surgical Research
Verified
Journal Article
Closed access
AIAmmar Ismail
Ammar Ismail
AAAbdelrahman Ibrahim Abushouk
Abdelrahman Ibrahim Abushouk
AEAhmed Elmaraezy
Ahmed Elmaraezy
AMAmr Menshawy
Amr Menshawy
EMEsraa Menshawy
Esraa Menshawy
EGEsraa Ghanem
Esraa Ghanem

5 May 2017 in The Journal of Vascular Access
Verified
Journal Article
Closed access
AIAmmar Ismail
Ammar Ismail
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
ABAmira H. Bekhet
Amira H. Bekhet
OAOsama Abunar
Osama Abunar
OHOmar Hassan
Omar Hassan
AEAhmed Elgebaly
Ahmed Elgebaly
There is a consensus in the literature that regional anesthesia (RA) improves local hemodynamic parameters in comparison to local anesthesia (LA) during arteriovenous fistula (AVF) surgical construction. However, the effects of both techniques on fistula patency and failure rates are still controversial. The aim of this meta-analysis is to synthesize evidence from published randomized trials and observational studies regarding the safety and efficacy of RA versus LA in AVF surgical construction. A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central retrieved six randomized trials (462 patients) and one retrospective study (408 patients). Pooling data using RevMan software (version 5.3) showed that RA was superior to LA in terms of primary fistula patency rate (RR = 1.22, 95% CI [1.08, 1.37], p = 0.0010); however, both types were comparable in terms of primary fistula failure rate (RR = 0.81, 95% CI [0.47, 1.40], p = 0.46). In comparison to LA, RA was associated with improved hemodynamic parameters including fistula blood flow (MD = 25.08, 95% CI [19.40, 30.76], p<0.00001), brachial artery diameter (SMD = 2.63, 95% CI [2.17, 3.08], p<0.00001), and outflow venous diameter (SMD = 0.93, 95% CI [0.30, 1.75], p = 0.004). Postoperative complications were comparable between both groups (OR = 0.23, 95% CI [0.05, 0.97], p = 0.05). In conclusion, RA was associated with higher primary patency rates of AVF and improved local blood flow in comparison to LA; however, both procedures were comparable in terms of primary failure rates and postoperative complications. Larger well-designed trials with longer follow-up periods should compare both techniques in terms of long-term patency rates and safety outcomes.

24 August 2017 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
AEAhmed Elmaraezy
Ahmed Elmaraezy
AIAmmar Ismail
Ammar Ismail
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
MEMoutaz Eltoomy
Moutaz Eltoomy
SSSoha Saad
Soha Saad
AAAmmar M. AlSafadi
Ammar M. AlSafadi
Recently, transcatheter aortic valve replacement (TAVR) has become the procedure of choice in high surgical risk patients with aortic stenosis (AS). However, its value is still debated in operable AS cases. We performed this meta-analysis to compare the safety and efficacy of TAVR to surgical aortic valve replacement (SAVR) in low-to-moderate surgical risk patients with AS. A systematic search of five authentic databases retrieved 11 eligible studies (20,056 patients). Relevant Data were pooled as risk ratios (RRs) or standardized mean differences (SMD), with their 95% confidence interval, using Comprehensive Meta-Analysis and RevMan software for windows. At one-year of follow-up, the pooled effect-estimates showed no significant difference between TAVR and SAVR groups in terms of all-cause mortality (RR 1.02, 95% CI [0.83, 1.26], stroke (RR 0.83, 95%CI [0.56, 1.21]), myocardial infarction (RR 0.82, 95% CI [0.57, 1.19]), and length of hospital stay (SMD -0.04, 95% CI [−0.34, 0.26]). The incidence of major bleeding (RR 0.45, 95% CI [0.24, 0.86]) and acute kidney injury (RR 0.52, 95% CI [0.30, 0.88]) was significantly lower in the TAVR group, compared to the SAVR group. However, TAVR was associated with a higher risk of permanent pacemaker implantation (RR 2.57, 95% CI [1.36, 4.86]), vascular-access complications at 1 year (RR 1.99, 95%CI [1.04, 3.80]), and paravalvular aortic regurgitation at 30 days (RR 3.90, 95% CI [1.25, 12.12]), compared to SAVR. Due to the comparable mortality rates in SAVR and TAVR groups and the lower risk of life-threatening complications in the TAVR group, TAVR can be an acceptable alternative to SAVR in low-to-moderate risk patients with AS. However, larger trials with longer follow-up periods are required to compare the long-term outcomes of both techniques.

5 August 2017 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
MEMostafa Wanees Ahmed El-Husseny
Mostafa Wanees Ahmed El-Husseny
MMMayar Magdy
Mayar Magdy
AIAmmar Ismail
Ammar Ismail
AAAttia Attia
Attia Attia
Ahmed NegidaAhmed Negida
Ahmed Negida

23 September 2017 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
AMAmr Menshawy
Amr Menshawy
HAHussien Ahmed
Hussien Ahmed
AIAmmar Ismail
Ammar Ismail
Abdelrahman AbushoukAbdelrahman Abushouk
Abdelrahman Abushouk
EGEsraa Ghanem
Esraa Ghanem
Ahmed NegidaAhmed Negida
Ahmed Negida